{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:49:25Z","timestamp":1792601365491,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12936-016-1329-z","type":"journal-article","created":{"date-parts":[[2016,5,17]],"date-time":"2016-05-17T03:55:21Z","timestamp":1463457321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pre-clinical evaluation of CYP 2D6 dependent drug\u2013drug interactions between primaquine and SSRI\/SNRI antidepressants"],"prefix":"10.1186","volume":"15","author":[{"given":"Xiannu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittney","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu-lan","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corttney","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qigui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Pybus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Kreishman-Deitrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Reichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Marcsisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,17]]},"reference":[{"key":"1329_CR1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1620\/tjem.211.99","volume":"211","author":"K Na-Bangchang","year":"2007","unstructured":"Na-Bangchang K, Congpuong K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. Tohoku J Exp Med. 2007;211:99\u2013113.","journal-title":"Tohoku J Exp Med"},{"key":"1329_CR2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12936-015-0838-5","volume":"14","author":"KM Lwin","year":"2015","unstructured":"Lwin KM, Imwong M, Suangkanarat P, Jeeyapant A, Vihokhern B, Wongsaen K, et al. Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malar J. 2015;14:319.","journal-title":"Malar J"},{"key":"1329_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1475-2875-13-51","volume":"13","author":"A Kondrashin","year":"2014","unstructured":"Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13:51.","journal-title":"Malar J"},{"key":"1329_CR4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.4269\/ajtmh.2011.11-0498","volume":"85","author":"HY Myint","year":"2011","unstructured":"Myint HY, Berman J, Walker L, Pybus B, Melendez V, Baird JK, et al. Review: improving the therapeutic index of 8-aminoquinolines by the use of drug combinations. Review of the literature and proposal for future investigations. Am J Trop Med Hyg. 2011;85:1010\u20134.","journal-title":"Am J Trop Med Hyg"},{"key":"1329_CR5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13318-013-0139-8","volume":"39","author":"X Jin","year":"2014","unstructured":"Jin X, Pybus BS, Marcsisin SR, Logan T, Luong TL, Sousa J, et al. An LC\u2013MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model. Eur J Drug Metab Pharmacokinet. 2014;39:139\u201346.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1329_CR6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1475-2875-11-259","volume":"11","author":"BS Pybus","year":"2012","unstructured":"Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J. 2012;11:259.","journal-title":"Malar J"},{"key":"1329_CR7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJMc1301936","volume":"369","author":"JW Bennett","year":"2013","unstructured":"Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369:1381\u20132.","journal-title":"N Engl J Med"},{"key":"1329_CR8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/1475-2875-13-507","volume":"13","author":"PS Fasinu","year":"2014","unstructured":"Fasinu PS, Tekwani BL, Nanayakkara NP, Avula B, Herath HM, Wang YH, et al. Enantioselective metabolism of primaquine by human CYP2D6. Malar J. 2014;13:507.","journal-title":"Malar J"},{"key":"1329_CR9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jms.3122","volume":"48","author":"B Avula","year":"2013","unstructured":"Avula B, Tekwani BL, Chaurasiya ND, Nanayakkara NP, Wang YH, Khan SI, et al. Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13C stable isotope labeling. J Mass Spectrom. 2013;48:276\u201385.","journal-title":"J Mass Spectrom"},{"key":"1329_CR10","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1016\/S0021-9258(19)50504-X","volume":"267","author":"J Vasquez-Vivar","year":"1992","unstructured":"Vasquez-Vivar J, Augusto O. Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J Biol Chem. 1992;267:6848\u201354.","journal-title":"J Biol Chem"},{"key":"1329_CR11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0006-2952(94)90022-1","volume":"47","author":"J Vasquez-Vivar","year":"1994","unstructured":"Vasquez-Vivar J, Augusto O. Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo. Biochem Pharmacol. 1994;47:309\u201316.","journal-title":"Biochem Pharmacol"},{"key":"1329_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.011","volume":"161","author":"SR Marcsisin","year":"2016","unstructured":"Marcsisin SR, Reichard G, Pybus BS. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art. Pharmacol Ther. 2016;161:1\u201310.","journal-title":"Pharmacol Ther"},{"key":"1329_CR13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12936-016-1270-1","volume":"15","author":"PS Fasinu","year":"2016","unstructured":"Fasinu PS, Avula B, Tekwani BL, Nanayakkara NP, Wang YH, Bandera HM, et al. Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes. Malar J. 2016;15:254.","journal-title":"Malar J"},{"key":"1329_CR14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/AAC.00015-15","volume":"59","author":"BM Potter","year":"2015","unstructured":"Potter BM, Xie LH, Vuong C, Zhang J, Zhang P, Duan D, et al. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59:2380\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1329_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12936-016-1145-5","volume":"15","author":"PL St Jean","year":"2016","unstructured":"St Jean PL, Xue Z, Carter N, Koh GC, Duparc S, Taylor M, et al. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malar J. 2016;15:97.","journal-title":"Malar J"},{"key":"1329_CR16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/11318070-000000000-00000","volume":"48","author":"SF Zhou","year":"2009","unstructured":"Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48:761\u2013804.","journal-title":"Clin Pharmacokinet"},{"key":"1329_CR17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1634\/theoncologist.11-2-126","volume":"11","author":"S Bernard","year":"2006","unstructured":"Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11:126\u201335.","journal-title":"Oncologist"},{"key":"1329_CR18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10549-013-2585-z","volume":"139","author":"L Binkhorst","year":"2013","unstructured":"Binkhorst L, Mathijssen RH, van Herk-Sukel MP, Bannink M, Jager A, Wiemer EA, van Gelder T. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat. 2013;139:923\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"1329_CR19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/11592620-000000000-00000","volume":"50","author":"M Tod","year":"2011","unstructured":"Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B. Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions. Clin Pharmacokinet. 2011;50:519\u201330.","journal-title":"Clin Pharmacokinet"},{"key":"1329_CR20","first-page":"572","volume":"69","author":"RD Gibbons","year":"2012","unstructured":"Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69:572\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"1329_CR21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/1745-7599.12016","volume":"25","author":"J Tawa","year":"2013","unstructured":"Tawa J, Murphy S. Psychopharmacological treatment for military posttraumatic stress disorder: an integrative review. J Am Assoc Nurse Pract. 2013;25:419\u201323.","journal-title":"J Am Assoc Nurse Pract"},{"key":"1329_CR22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206\u201327.","journal-title":"Clin Ther"},{"key":"1329_CR23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","volume":"34","author":"HK Crewe","year":"1992","unstructured":"Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34:262\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"1329_CR24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/00912700022008702","volume":"40","author":"CL Alfaro","year":"2000","unstructured":"Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40:58\u201366.","journal-title":"J Clin Pharmacol"},{"key":"1329_CR25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40262-015-0315-x","volume":"55","author":"L Binkhorst","year":"2015","unstructured":"Binkhorst L, Bannink M, de Bruijn P, Ruit J, Droogendijk H, van Alphen RJ, et al. Augmentation of endoxifen exposure in tamoxifen-treated women following SSRI switch. Clin Pharmacokinet. 2015;55:249\u201355.","journal-title":"Clin Pharmacokinet"},{"key":"1329_CR26","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","volume":"95","author":"V Stearns","year":"2003","unstructured":"Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758\u201364.","journal-title":"J Natl Cancer Inst"},{"key":"1329_CR27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1475-2875-12-212","volume":"12","author":"BS Pybus","year":"2013","unstructured":"Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12:212.","journal-title":"Malar J"},{"key":"1329_CR28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.vascn.2014.08.002","volume":"70","author":"X Jin","year":"2014","unstructured":"Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, et al. Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for anti-malarial drug screening and drug investigations. J Pharmacol Toxicol Methods. 2014;70:188\u201394.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"1329_CR29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1475-2875-13-141","volume":"13","author":"Q Li","year":"2014","unstructured":"Li Q, O\u2019Neil M, Xie L, Caridha D, Zeng Q, Zhang J, et al. Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections. Malar J. 2014;13:141.","journal-title":"Malar J"},{"key":"1329_CR30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00004714-200104000-00007","volume":"21","author":"AT Harvey","year":"2001","unstructured":"Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001;21:161\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"1329_CR31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2125.1997.00591.x","volume":"43","author":"SE Ball","year":"1997","unstructured":"Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol. 1997;43:619\u201326.","journal-title":"Br J Clin Pharmacol"},{"key":"1329_CR32","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1592\/phco.22.12.1001.33603","volume":"22","author":"YW Lam","year":"2002","unstructured":"Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy. 2002;22:1001\u20136.","journal-title":"Pharmacotherapy"},{"key":"1329_CR33","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1128\/AAC.03704-14","volume":"58","author":"B Hanboonkunupakarn","year":"2014","unstructured":"Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014;58:7340\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"1329_CR34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1128\/AAC.03829-14","volume":"59","author":"P Jittamala","year":"2015","unstructured":"Jittamala P, Pukrittayakamee S, Ashley EA, Nosten F, Hanboonkunupakarn B, Lee SJ, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59:505\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"1329_CR35","first-page":"301","volume":"46","author":"AS Alving","year":"1955","unstructured":"Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955;46:301\u20136.","journal-title":"J Lab Clin Med"},{"key":"1329_CR36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/1475-2875-13-488","volume":"13","author":"RJ Ingram","year":"2014","unstructured":"Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J. 2014;13:488.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-016-1329-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T06:55:06Z","timestamp":1692341706000},"score":1,"resource":{"primary":{"URL":"http:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-016-1329-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1186\/s12936-016-1329-z","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,17]]},"article-number":"280"}}